Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8A4Q

crystal structures of diastereomer (R,S,S)-13b (13b-H) in complex with the SARS-CoV-2 Mpro.

8A4Q の概要
エントリーDOI10.2210/pdb8a4q/pdb
分子名称3C-like proteinase nsp5, ~{tert}-butyl ~{N}-[1-[(2~{R})-3-cyclopropyl-1-oxidanylidene-1-[[(2~{S},3~{S})-3-oxidanyl-4-oxidanylidene-1-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]-4-[(phenylmethyl)amino]butan-2-yl]amino]propan-2-yl]-2-oxidanylidene-pyridin-3-yl]carbamate, DIMETHYL SULFOXIDE, ... (5 entities in total)
機能のキーワードsarscov2, covid19, mpro, 3clpro, inhibitor, antiviral protein
由来する生物種Severe acute respiratory syndrome coronavirus 2
タンパク質・核酸の鎖数1
化学式量合計34612.95
構造登録者
Ibrahim, M.,Hilgenfeld, R.,Zhang, L. (登録日: 2022-06-13, 公開日: 2022-10-12, 最終更新日: 2024-02-07)
主引用文献Cooper, M.S.,Zhang, L.,Ibrahim, M.,Zhang, K.,Sun, X.,Roske, J.,Gohl, M.,Bronstrup, M.,Cowell, J.K.,Sauerhering, L.,Becker, S.,Vangeel, L.,Jochmans, D.,Neyts, J.,Rox, K.,Marsh, G.P.,Maple, H.J.,Hilgenfeld, R.
Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.
J.Med.Chem., 65:13328-13342, 2022
Cited by
PubMed Abstract: SARS-CoV-2 is the causative agent behind the COVID-19 pandemic. The main protease (M, 3CL) of SARS-CoV-2 is a key enzyme that processes polyproteins translated from the viral RNA. M is therefore an attractive target for the design of inhibitors that block viral replication. We report the diastereomeric resolution of the previously designed SARS-CoV-2 M α-ketoamide inhibitor . The pure ()-diastereomer, , displays an IC of 120 nM against the M and EC values of 0.8-3.4 μM for antiviral activity in different cell types. Crystal structures have been elucidated for the M complexes with each of the major diastereomers, the active ()-13b (), and the nearly inactive ()-13b (); results for the latter reveal a novel binding mode. Pharmacokinetic studies show good levels of after inhalative as well as after peroral administration. The active inhibitor () is a promising candidate for further development as an antiviral treatment for COVID-19.
PubMed: 36179320
DOI: 10.1021/acs.jmedchem.2c01131
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.75 Å)
構造検証レポート
Validation report summary of 8a4q
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon